The DaiSyBio lab at TUM School of Life Sciences is a partner of the REPO4EU project funded under Horizon Europe with 23 Mio €.
The aim is to develop a platform for mechanism-based drug repurposing. Rather than defining a disease by its symptoms, this project aims to define diseases by the affected molecular mechanism. These mechanisms are extracted from molecular interaction networks and can be used to suggest drug repurposing candidates, i.e., already approved drugs that we can use to treat these new indications.
TUM contributes to developing an integrated multi-scale knowledge platform and a pipeline for disease module identification applicable to various use cases ranging from cancer to rare diseases.
RExPO conference
Key topics: Rare diseases, network medicine, pharmacology, precision diagnostics, drug reformulation, patient engagement, innovative trials, regulatory science, AI in healthcare and much more
TUM Speakers: Prof. Mathias Wilhelm, Prof. Hannelore Meyer
TUM Poster presentations: Johannes Kersting, Matthew The, Lisa Spindler
| Date | July 3-5, 2024 |
| Location | Die Macherei München, Weihenstephaner Str. 12 |
| Organizer | REPO4EU Horizon Europe Projekt (Harald H.H.W. Schmidt, Chair of Pharmacology at Maastricht University / Project Coordinator and Jennifer Martin, Chair of Clinical Pharmacology at University of Newcastle) |
| Registration | Yes, required. Register here |